Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

Cameron, D, Morden, JP, Canney, P et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045

Abstract

Metadata

Authors/Creators:
  • Cameron, D
  • Morden, JP
  • Canney, P
  • Velikova, G https://orcid.org/0000-0003-1899-5942
  • Coleman, R
  • Bartlett, J
  • Agrawal, R
  • Banerji, J
  • Bertelli, G
  • Bloomfield, D
  • Brunt, AM
  • Earl, H
  • Ellis, P
  • Gaunt, C
  • Gillman, A
  • Hearfield, N
  • Laing, R
  • Murray, N
  • Couper, N
  • Stein, RC
  • Verrill, M
  • Wardley, A
  • Barrett-Lee, P
  • Bliss, JM
Copyright, Publisher and Additional Information: © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Dates:
  • Published: July 2017
  • Accepted: 10 May 2017
  • Published (online): 6 June 2017
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 08 Jun 2017 12:03
Last Modified: 12 Jul 2017 09:42
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S1470-2045(17)30404-7

Share / Export

Statistics